ARNA Genomics introduces a revolutionary solution for cancer diagnostics and treatment biotechnologies — blockchain-ecosystem ARNA Panacea.
White Paper — https://token.arnagenomics.com/ARNA_whitepaper_en.pdf
ARNA Panacea by design is platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients).
The platform’s initial purpose is to gain, store and analyze information on all the methods of cancer detection and treatment from all over the world. This would allow researchers getting more accurate and precise knowledge on the subject on one hand, and on the other — will provide trustable and accessible proof to all market participants on research results conducted throughout their lifecycle.
According to ARNA Panacea concept, researchers would be able to keep in blockchain a researcher's diary — a necessary tool of all researchers — in which they will keep encrypted their research data (plans of experiments, thoughts and ideas, results of experiments, etc.). However, during R&D phase each researcher would be able to uncover some of his ideas or results to other platform users, thus creating an unprecedented opportunity for researchers to cooperate without risks of their ideas being misappropriated by others without any proof of discovery.
The other functionality of platform is utilizing power of cryptographic tokens specifically designed, so holders will have an opportunity to pay for member services, that include diagnostic tests during cancer check-ups and many more.
Why does ARNA Panacea deserves such titles as “revolutionary” and “game-changing”? Despite using already existing technological basements and methodologies, the Project bears one of the simplest principle of work: store all clinical trials and further product usage data using the blockchain technology jointly with providing unprecedented opportunity for all platform members to make direct payments to each other using crypto tokens for defined by platform design services. This allows the system to be more efficient and provide its members with a reliable ecosystem, connecting regulators, clinics, MDs, CROs, insurance companies, pharmaceutical companies, investors, researchers, experts, patients and other participants in one place.
The Company is not only proposing a disruptive ecosystem for healthcare and biotech, but also provides the first innovative DNA breast cancer test with unique technology of DNA extracting and analyzing – ARNA BC – which according to laboratory trials has extremely high accuracy, sensitivity and specificity of more than 95% even at early breast cancer stages. However, these parameters need to be proved by independent clinical trial, which, if successful, would allow to save a lot of lives according to available statistics. ARNA Genomics claims that all clinical trials will be posted to currently developing Panacea system, thus making everybody including token holders to track trials results in almost real-time mode, which has never been available before. Besides, there are further tests being in R&D phase currently, data on which will be also posted to the system as well as ARNA tokens will be used.
ARNA tokens are the open source cryptographic tokens designed to be a fixed-value crypto currency which is proof to inflation. 50% of the revenues from the implementation of ARNA tokens will be targeted to development of first production release of ARNA Panacea as well as an official clinical trial of the ARNA BC under the supervision and condition by the FDA (Food and Drug Administration of the United States).
The overall balance of funds will be spent to create a vast network of DNA testing laboratories in the key cities of the US. There is also a plan to register and start sales to patients of ARNA BC test in Russian Federation – the price of such step would be significantly lower if the system is implemented in the developing country and will help to start gathering statistical data. The growing market of Russia as well as its proximity to Europe also provides the company with more system members in the future. The overall potential market for ARNA BC in US and Russia is conservatively estimated at 40 million tests per year.
The overall cost of the initial project is estimated at about $40 million over 3 years after the ICO. ARNA Genomics also offers an unprecedented option to buy ARNA BC company shares in future at very low nominal value for heavy token holders immediately after ARNA BC will pass FDA trials, however subject to regulatory approval.
What are the standards of tokens?
ARNA tokens and the Utility Tokens are not subjected by the SEC (Security and Exchange Commission of the United States). The issue of the tokens will be applied on the open blockchain Ethereum as standard ERC20.
The main advantage of this solution is that the Ethereum blockchain is the current standard for digital assets and smart contacts. ERC20 token interface is capable of deploying a standard token that is compatible with already available infrastructure of the Ethereum ecosystem. This also includes development tools, wallets and exchangers.
How to acquire the ARNA tokens?
Offering of ARNA tokens will start at first as pre-sale, starting September, 21 with a 10% discount to the main token sale, which is planned on November, 19. Only ETH (Ether) will be accepted during both pre- and main sales, however other crypto currencies can be converted by ShapeShift.io into ETH automatically during the main sale event.
Pre-sale cap is 1 million USD equivalent — this is a budgeted amount not only for successful marketing of the project before the main sale, but also a first input to start actions of products development and approval according to the Company’s strategy without waiting for main token sale to complete. The participant should register by filling out the form on https://token.arnagenomics.com/
To finance activities in accordance to the plan, the Company will distribute tokens in the form of a limited time. Maximum sales amount of 50% of ARNA tokens from the total amount of issued tokens — 1.000.000.000 (one billion).
The members of the project team will distribute around 25% tokens to motivate the work team, various advisors required for such ambitious project to be implemented and founders. The first distribution will be proceeded the initial sale of the tokens will be completed to compensate the contribution of individual members of the initiative, but the major part will be vested over time to ensure long-term and effective commitment of everyone towards the project’s success.
25% of all the tokens will be reserved to enter into mutually beneficial deals with future potential partners for the purposes of promotion, including the ARNA Panacea platform itself.
The ultimate release of the platform is planned on 2018.